...
首页> 外文期刊>Trends in Microbiology >Cellular entry of the SARS coronavirus
【24h】

Cellular entry of the SARS coronavirus

机译:SARS冠状病毒的细胞进入

获取原文
获取原文并翻译 | 示例

摘要

Enveloped viruses have evolved membrane glycoproteins (GPs) that mediate entry into host cells. These proteins are important targets for antiviral therapies and vaccines. Several efforts to understand and combat infection by severe acute respiratory syndrome coronavirus (SARS-CoV) have therefore focused on the viral GP, known as spike (S). In a short period of time, important aspects of SARS-CoV S-protein function were unraveled. The identification of angiotensin-converting enzyme 2 (ACE2) as a receptor for SARS-CoV provided an insight into viral tropism and pathogenesis, whereas mapping of functional domains in the S-protein enabled inhibitors to be generated. Vaccines designed on the basis of SARS-CoV S-protein were shown to be effective in animals and consequently are attractive candidates for vaccine trials in humans. Here, we discuss how SARS-CoV S facilitates viral entry into target cells and illustrate current approaches that are used to inhibit this process.
机译:包膜病毒已经进化出膜糖蛋白(GPs),介导进入宿主细胞。这些蛋白质是抗病毒治疗和疫苗的重要靶标。因此,为了解和抵抗严重急性呼吸系统综合症冠状病毒(SARS-CoV)感染所做的几项努力都集中在病毒GP上,即所谓的穗状病毒(S)。在短时间内,SARS-CoV S蛋白功能的重要方面得以阐明。血管紧张素转换酶2(ACE2)作为SARS-CoV受体的鉴定为病毒嗜性和致病机理提供了见识,而在S蛋白中功能域的定位则可以产生抑制剂。已显示基于SARS-CoV S蛋白设计的疫苗对动物有效,因此是在人体中进行疫苗试验的诱人候选物。在这里,我们讨论SARS-CoV S如何促进病毒进入靶细胞,并说明当前用于抑制该过程的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号